Project 3: Modeling and overcoming resistance to melanoma immunotherapy
项目 3:建模并克服黑色素瘤免疫疗法的耐药性
基本信息
- 批准号:10261398
- 负责人:
- 金额:$ 51.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-11 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAgonistAnimalsAntigen PresentationAntigensAwardBioinformaticsBiologyBiometryBiopsyCRISPR/Cas technologyCell LineCellsChemosensitizationClinical TrialsCollaborationsCombined Modality TherapyDataEnrollmentEpigenetic ProcessExclusionGene ExpressionGeneticGoalsHumanImmuneImmunotherapyIn VitroInterferon ReceptorInterferon Type IIInterferonsJAK1 geneJAK2 geneKnock-outKnowledgeLaboratoriesLaboratory ResearchLeadLearningMalignant NeoplasmsMediatingMelanoma CellMinorityModelingMolecularMolecular BiologyMusMutationNatural Killer CellsNivolumabPD-1 blockadePathologicPathologyPathway interactionsPatient CarePatientsPharmacologyPhosphotransferasesPositioning AttributeProcessReagentReportingResearchResearch PersonnelResistanceResistance ProcessRoleSamplingT-LymphocyteTestingTissuesToll-like receptorsanti-PD-1anti-PD1 antibodiesanti-PD1 therapybasecancer cellcancer immunotherapydesigngenetic resistanceimprovedin vivo Modelinhibitor/antagonistloss of functionloss of function mutationmelanomamouse modelnon-geneticpreventprogrammed cell death protein 1programsresistance mechanismresponsestandard of carestatisticstargeted treatmenttherapy resistanttumor
项目摘要
PROJECT 3 ABSTRACT
We have started to make progress in defining mechanisms that lead to primary and acquired resistance to anti-
PD-1/L1 therapy at the molecular level. In this Project, we propose to characterize their biology, discover how
to overcome resistance based on mechanistic understanding, and study how this knowledge can improve
patient care. In Aim 1, we will develop in vitro and in vivo models to study the biology of molecularly-defined
resistance mechanisms with the goal of providing full mechanistic understanding of how they mediate
resistance. This is based on our discovery of homozygous loss of function (LoF) mutations in the interferon
(IFN) receptor pathway and in the antigen presenting machinery (APM) in biopsies of patients with primary and
acquired resistance to PD-1 blockade therapy, both confirmed with data from other groups. With this
information, we will be in the position to test combination approaches to overcome resistance to anti-PD-1/L1
therapy. These include approaches aimed at inducing a local IFN response that may activate this pathway
downstream, such as toll-like receptor (TLR) or MDA5 agonists in JAK1/2 knockout models, and activating
natural killer (NK) cells in B2M knockout models. In Aim 2, we will study a new cancer cell-intrinsic
mechanisms of T cell exclusion mediated by the expression of the p21 associated kinase 4 (PAK4), which we
have recently uncovered by comparing gene expression in T cell-rich versus T cell-poor biopsies of patients
with melanoma on therapy with anti-PD-1. We will examine the mechanisms leading to T cell exclusion
induced by PAK4 in mouse models, and we will analyze the mechanisms in biopsies obtained from patients
enrolled in a clinical trial combining the PAK4 inhibitor KPT-9274 and the anti-PD-1 antibody nivolumab.
Sample analyses for the two aims will benefit from the collaboration with investigators from the other two
projects and cores of this P01. In conclusion, this Project will analyze defined mechanisms of therapeutic
resistance to cancer immunotherapy to provide improved understanding on their effects, and show how to
overcome the resistance using rationally designed combination studies.
1
项目3摘要
我们已经开始在确定导致对抗-HCV的原发性和获得性耐药性的机制方面取得进展,
分子水平的PD-1/L1治疗。在这个项目中,我们建议描述它们的生物学特征,
克服基于机械理解的阻力,并研究如何利用这些知识提高
病人护理在目标1中,我们将开发体外和体内模型来研究分子定义的
抗性机制,目的是提供对它们如何介导
阻力这是基于我们发现的干扰素基因中的纯合性功能丧失(LoF)突变。
(IFN)受体途径和原发性和非原发性肝癌患者活检中的抗原递呈机制(APM)
对PD-1阻断治疗获得性耐药,这两个结果都得到了其他组数据的证实。与此
信息,我们将能够测试组合方法,以克服抗PD-1/L1的耐药性
疗法这些方法包括旨在诱导局部IFN应答,从而激活该途径
下游,如JAK 1/2敲除模型中的toll样受体(TLR)或MDA 5激动剂,以及激活
在B2 M敲除模型中的自然杀伤(NK)细胞。在目标2中,我们将研究一种新的癌细胞--内源性
p21相关激酶4(PAK 4)表达介导的T细胞排斥机制,我们
最近通过比较患者T细胞丰富和T细胞缺乏的活检组织中的基因表达,
黑色素瘤患者接受抗PD-1治疗我们将研究导致T细胞排斥的机制
在小鼠模型中,我们将分析从患者获得的活检组织中的机制,
参加了一项结合PAK 4抑制剂KPT-9274和抗PD-1抗体nivolumab的临床试验。
这两个目标的样本分析将受益于与其他两个目标的研究人员的合作
P01的项目和核心。总之,本项目将分析治疗的定义机制,
抵抗癌症免疫疗法,以提供更好的了解他们的影响,并显示如何
利用合理设计的组合研究克服阻力。
1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTONI RIBAS其他文献
ANTONI RIBAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTONI RIBAS', 18)}}的其他基金
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
项目 3:建模并克服黑色素瘤免疫疗法的耐药性
- 批准号:
10025138 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
项目 3:建模并克服黑色素瘤免疫疗法的耐药性
- 批准号:
10693132 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
项目 3:建模和克服黑色素瘤免疫疗法的耐药性
- 批准号:
10443861 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
Combination Therapies to Defeat Melanoma Resistance
击败黑色素瘤耐药性的联合疗法
- 批准号:
10443858 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
Combination Therapies to Defeat Melanoma Resistance
击败黑色素瘤耐药性的联合疗法
- 批准号:
10025135 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
Combination Therapies to Defeat Melanoma Resistance
击败黑色素瘤耐药性的联合疗法
- 批准号:
10261395 - 财政年份:2020
- 资助金额:
$ 51.79万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 51.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)